SomaGen Collaborates with Stanford University on Joint Research to Uncover Correlation Between Autism Symptoms and Microbiome

[Asia Economy Reporter Hyunseok Yoo] Somagen, the first foreign company to be listed through the special technology listing in the U.S., announced on the 24th that it signed a joint research agreement on the 19th with Stanford University School of Medicine titled ‘Identification of the Correlation between Autism Symptoms, Gut Microbiome, and the Human Genome and Discovery of Biomarkers.’

This is the world’s first large-scale research project to identify the correlation between autism and the microbiome. It is scheduled to proceed over the next two years. During this period, Stanford University will be responsible for recruiting samples from autism patients as well as developing and analyzing machine learning algorithms. Somagen will provide its comprehensive GutBiome analysis platform, a gut microbiome analysis service.

The joint research and development will involve Dr. Dennis P. Wall, a professor of Pediatrics, Psychiatry, and Biomedical Data Science at Stanford University School of Medicine, along with his research team.

Ryan Kim, CEO of Somagen, stated, "The joint research and development with Stanford University not only provides an opportunity to enhance Somagen’s global recognition in the global microbiome analysis market but also marks a significant first step toward the commercialization of autism diagnosis and treatment methods using the microbiome." He added, "We plan to actively develop clinical microbiome diagnostic services capable of diagnosing not only autism but also various diseases and disorders.”

This content was produced with the assistance of AI translation services.